|
1
|
Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein.
Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, Orekhov AN
Atherosclerosis 2001 Nov 159(1):103-115.
|
|
2
|
Continuous subendothelial network formed by pericyte-like cells in human vascular bed.
Andreeva ER, Pugach IM, Gordon D, Orekhov AN
Tissue Cell 1998 Feb 30(1):127-135.
|
|
3
|
Low-density lipoprotein modification occurring in human plasma possible mechanism of in vivo lipoprotein desialylation as a primary step of atherogenic modification.
Tertov VV, Kaplun VV, Sobenin IA, Orekhov AN
Atherosclerosis 1998 May 138(1):183-195
|
|
4
|
In vivo oxidized low density lipoprotein: degree of lipoprotein oxidation does not correlate with its atherogenic properties.
Tertov VV, Kaplun VV, Orekhov AN
Mol Cell Biochem 1998 Jun 183(1-2):141-146.
|
|
5
|
Cell proliferation in normal and atherosclerotic human aorta: proliferative splash in lipid-rich lesions.
Orekhov AN, Andreeva ER, Mikhailova IA, Gordon D
Atherosclerosis 1998 Jul 139(1):41-48.
|
|
6
|
Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro.
Tertov VV, Sobenin IA, Kaplun VV, Orekhov AN
Free Radic Res 1998 Aug 29(2):165-173.
|
|
7
|
Optimization of the assay for sialic acid determination in low density lipoprotein.
Sobenin IA, Tertov VV, Orekhov AN
J Lipid Res 1998 Nov 39(11):2293-2299.
|
|
8
|
Многофакторная профилактика атеросклероза и атеросклеротических заболеваний.
Собенин ИА, Орехов АН
Medicina Altera 1999 июль/сентябрь:7-16.
|
|
9
|
Применение алликора для коррекции метаболизма при сахарном диабете: биохимические предпосылки и клинические исследования.
Собенин ИА, Недосугова ЛВ, Филатова ЛВ, Медведева ЛА, Скалбе ТА, Балаболкин МИ, Орехов АН
Medicina altera 2000 декабрь:3-8.
|
